ERIS Lifesciences Ltd (ERIS)
₹1,156.40
Mkt cap
₹16,044 Cr
P/E ratio
21.50
P/B
3.87
Div yield
0.62%
ROE
18.70%
ROCE
14.10%
EPS (TTM)
₹53.79
Book value
₹299
52W range
1,069–1,740
Sector
Healthcare
Price history
Previous close
ERIS Lifesciences Ltd is engaged in the business of manufacture and marketing of pharmaceutical products. [1]
NSE ERISBSE 540596
Health check
Constructive
ValuationCheap
ProfitabilityAverage
GrowthHigh
TechnicalsBearish
52-week range
−33.54% from high₹1,156
₹1,069+8.18% from low₹1,740
Current
₹1,156.40
Prev close
₹1,163.60
Day
−0.62%
Price performance
1D
−0.83%
1W
+5.34%
1M
−5.36%
3M
−16.08%
6M
−12.32%
1Y
−27.40%
YTD
−24.59%
Financials
Revenue, profit & margin
P/E ratio
21.5×
ERIS is 37% below the sector median of 34.0×
ERIS21.5×
Sector median34.0×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 505 | 486 | 551 | 720 | 741 | 727 | 705 | 773 | 792 | 807 | 757 | 873 | 892 | |
| Expenses | 324 | 311 | 402 | 470 | 477 | 477 | 453 | 496 | 504 | 526 | 484 | 577 | 584 | |
| Operating Profit | 181 | 176 | 148 | 250 | 265 | 250 | 252 | 277 | 288 | 282 | 272 | 296 | 308 | |
| OPM % | 36% | 36% | 27% | 35% | 36% | 34% | 36% | 36% | 36% | 35% | 36% | 34% | 35% | |
| Other Income | 3 | 4 | 15 | 2 | 5 | 4 | 8 | 4 | 3 | -17 | 2 | 2 | -33 | |
| Interest | 16 | 18 | 33 | 60 | 59 | 57 | 54 | 49 | 50 | 49 | 46 | 47 | 46 | |
| Depreciation | 42 | 46 | 54 | 76 | 80 | 81 | 77 | 71 | 69 | 70 | 70 | 72 | 73 | |
| Profit before tax | 126 | 116 | 77 | 116 | 129 | 116 | 129 | 161 | 173 | 145 | 159 | 179 | 156 | |
| Tax % | 3% | 12% | -4% | 22% | 25% | 25% | 21% | 22% | 22% | 25% | -75% | 20% | -20% | |
| Net Profit | 122 | 101 | 80 | 90 | 96 | 87 | 102 | 125 | 134 | 109 | 279 | 143 | 187 | |
| EPS in Rs | 9.07 | 7.55 | 5.22 | 6.12 | 6.73 | 6.15 | 6.89 | 8.66 | 8.82 | 7.32 | 20.33 | 10.28 | 13.25 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −0.17% · closed higher next day 17 of last 36
| Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | Q2FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 14 Feb '24◦ | 22 May '24◦ | 3 Aug '24◦ | 25 Oct '24◦ | 5 Feb '25 | 19 May '25◦ | 5 Aug '25 | 12 Nov '25◦ | 13 Feb '26 | 20 May '26 | 29 Jul '26 | 26 Oct '26 |
| Earnings day | −1.05% | −2.47% | −3.76% | −0.85% | +12.85% | +1.84% | +0.28% | −3.62% | −6.36% | +9.13% | +2.57% | +0.89% |
| +1 day | +2.66% | −3.30% | −1.27% | +0.82% | +18.01% | +4.31% | −4.34% | −1.57% | −9.67% | +3.72% | −1.12% | +9.39% |
| +5 days | +0.31% | +0.59% | +7.59% | +1.51% | +5.69% | +8.78% | −6.86% | +5.99% | −11.12% | +1.09% | −1.13% | — |
| +15 days | +4.82% | +12.73% | +15.30% | +5.80% | −1.32% | +17.18% | −0.59% | −0.97% | −12.05% | +2.20% | −3.06% | — |
| +30 days | −2.36% | +11.49% | +24.36% | +17.10% | +12.91% | +16.13% | −9.26% | −3.13% | −13.25% | +7.10% | −4.01% | — |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Interim Dividend - Rs 7.21 Per Share | 7.21 | 29 May '26 | 29 May '26 |
Shareholding
as of Sep 202654.74%Promoter
Promoters54.74%0.60
FIIs5.74%0.02
DIIs20.19%0.52
Public19.32%0.07
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,777.70 | 34.66 | 4,26,530 | 0.90% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹9,780.00 | 87.14 | 2,59,628 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,613.40 | 80.83 | 1,75,479 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,405.50 | 97.00 | 1,29,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,245.50 | 25.52 | 1,24,239 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,352.00 | 40.30 | 1,12,849 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,378.90 | 35.87 | 1,11,397 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| ERIS Lifescience | ₹1,156.40 | 21.48 | 16,044 | 0.62% | 187 | +75.96% | 892 | +12.61% | 14.13% |
| Median: 158 Co. | ₹426.38 | 34.03 | 1,921 | 0.08% | 14 | +24.68% | 175 | +19.54% | 15.12% |
Filings
Annual reports10
Concall transcripts78
PPTOct 2026RECOct 2026TranscriptJul 2026PPTJul 2026RECJul 2026TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptFeb 2026PPTFeb 2026TranscriptNov 2025PPTNov 2025TranscriptAug 2025PPTAug 2025TranscriptMay 2025PPTMay 2025TranscriptFeb 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024TranscriptAug 2024PPTAug 2024TranscriptJun 2024PPTJun 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 29 Oct - Company will host "Eris Investor Meet - 2026" on November 19, 2026Announcement under Regulation 30 (LODR)-Earnings Call Transcript 29 OctAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 26 Oct - Earnings conference call recording for Q2 FY27 results is available on company website.Announcement under Regulation 30 (LODR)-Investor Presentation 26 OctFinancial Results For Quarter And Half Year Ended September 30, 2026 26 Oct